NL9200423A - Farmaceutische samenstelling die als aktieve ingredient 3-/2-(dimethylamino)-ethyl/-n-methyl-1h-indool-5-methaansulfonamide bevat. - Google Patents
Farmaceutische samenstelling die als aktieve ingredient 3-/2-(dimethylamino)-ethyl/-n-methyl-1h-indool-5-methaansulfonamide bevat. Download PDFInfo
- Publication number
- NL9200423A NL9200423A NL9200423A NL9200423A NL9200423A NL 9200423 A NL9200423 A NL 9200423A NL 9200423 A NL9200423 A NL 9200423A NL 9200423 A NL9200423 A NL 9200423A NL 9200423 A NL9200423 A NL 9200423A
- Authority
- NL
- Netherlands
- Prior art keywords
- pharmaceutical composition
- active ingredient
- methyl
- indole
- composition according
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 title claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 16
- -1 2- (DIMETHYLAMINO) -ETHYL Chemical class 0.000 title description 12
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 208000019695 Migraine disease Diseases 0.000 claims abstract description 11
- 206010027599 migraine Diseases 0.000 claims abstract description 9
- 239000012453 solvate Substances 0.000 claims abstract description 9
- 239000003826 tablet Substances 0.000 claims description 20
- 238000000576 coating method Methods 0.000 claims description 18
- 239000011248 coating agent Substances 0.000 claims description 15
- 239000011247 coating layer Substances 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims description 9
- 206010019233 Headaches Diseases 0.000 claims description 7
- 231100000869 headache Toxicity 0.000 claims description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 7
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 3
- SZILWAWKHRWITL-UHFFFAOYSA-N 1-(1h-indol-5-yl)-n-methylmethanesulfonamide Chemical compound CNS(=O)(=O)CC1=CC=C2NC=CC2=C1 SZILWAWKHRWITL-UHFFFAOYSA-N 0.000 claims description 2
- 208000006561 Cluster Headache Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 206010043269 Tension headache Diseases 0.000 claims description 2
- 208000008548 Tension-Type Headache Diseases 0.000 claims description 2
- 208000018912 cluster headache syndrome Diseases 0.000 claims description 2
- 239000007891 compressed tablet Substances 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 abstract 2
- 208000002193 Pain Diseases 0.000 abstract 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000008213 purified water Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000004408 titanium dioxide Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 239000007919 dispersible tablet Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 2
- 239000001087 glyceryl triacetate Substances 0.000 description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000003973 paint Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229960002622 triacetin Drugs 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010009094 Chronic paroxysmal hemicrania Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 208000007777 paroxysmal Hemicrania Diseases 0.000 description 1
- 238000009512 pharmaceutical packaging Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940023144 sodium glycolate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical compound BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Waveguide Aerials (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Non-Reversible Transmitting Devices (AREA)
- Control Of Motors That Do Not Use Commutators (AREA)
- Medicines Containing Plant Substances (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9104890 | 1991-03-08 | ||
| GB919104890A GB9104890D0 (en) | 1991-03-08 | 1991-03-08 | Compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL9200423A true NL9200423A (nl) | 1992-10-01 |
Family
ID=42342461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL9200423A NL9200423A (nl) | 1991-03-08 | 1992-03-06 | Farmaceutische samenstelling die als aktieve ingredient 3-/2-(dimethylamino)-ethyl/-n-methyl-1h-indool-5-methaansulfonamide bevat. |
Country Status (29)
| Country | Link |
|---|---|
| US (4) | US5863559A (de) |
| EP (1) | EP0503440B1 (de) |
| JP (1) | JP2986546B2 (de) |
| KR (1) | KR100202042B1 (de) |
| AT (1) | ATE165973T1 (de) |
| AU (1) | AU663303B2 (de) |
| BE (1) | BE1005086A5 (de) |
| CA (1) | CA2105180C (de) |
| CH (1) | CH684242A5 (de) |
| CY (1) | CY2011A (de) |
| CZ (1) | CZ282352B6 (de) |
| DE (1) | DE69225421T2 (de) |
| DK (1) | DK0503440T3 (de) |
| ES (1) | ES2117015T3 (de) |
| FR (1) | FR2673538B1 (de) |
| GB (2) | GB9104890D0 (de) |
| GE (1) | GEP20012549B (de) |
| HK (1) | HK19395A (de) |
| IE (1) | IE920726A1 (de) |
| IL (1) | IL101162A (de) |
| IT (1) | IT1271495B (de) |
| MX (1) | MX9200992A (de) |
| NL (1) | NL9200423A (de) |
| NZ (1) | NZ241873A (de) |
| OA (1) | OA09812A (de) |
| RU (1) | RU2098093C1 (de) |
| SG (1) | SG169294G (de) |
| WO (1) | WO1992015295A1 (de) |
| ZA (1) | ZA921690B (de) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9104890D0 (en) * | 1991-03-08 | 1991-04-24 | Glaxo Group Ltd | Compositions |
| DE69222006T2 (de) * | 1991-10-30 | 1998-01-22 | Glaxo Group Ltd | Mehrschichtzusammensetzungen enthaltend Histamin- oder Serotonin- Antagonisten |
| DE4314976C1 (de) * | 1993-05-06 | 1994-10-06 | Lohmann Therapie Syst Lts | Transdermale therapeutische Systeme zur Verabreichung von Wirkstoffen, Verfahren zu ihrer Herstellung und ihre Verwendung |
| US8022095B2 (en) * | 1996-08-16 | 2011-09-20 | Pozen, Inc. | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
| US7189753B1 (en) | 1997-11-06 | 2007-03-13 | Cady Roger K | Preemptive prophylaxis of migraine |
| US6066092A (en) * | 1997-11-06 | 2000-05-23 | Cady; Roger K. | Preemptive prophylaxis of migraine device and method |
| GB9924717D0 (en) * | 1999-10-19 | 1999-12-22 | Glaxo Group Ltd | Diagnostic |
| AT500063A1 (de) | 1999-11-23 | 2005-10-15 | Sandoz Ag | Beschichtete tablettenkerne |
| AU2001296908A1 (en) * | 2000-09-29 | 2002-04-08 | Geneva Pharmaceuticals, Inc. | Proton pump inhibitor formulation |
| US20030070584A1 (en) * | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing cellulose ethers |
| AU4061702A (en) * | 2001-05-15 | 2003-04-03 | Mcneil-Ppc, Inc. | Dip coating compositions containing starch or dextrin |
| US8329734B2 (en) * | 2009-07-27 | 2012-12-11 | Afgin Pharma Llc | Topical therapy for migraine |
| DK1435945T3 (da) * | 2001-06-05 | 2008-12-01 | Ronald Aung-Din | Topisk migræne terapi |
| US8309118B2 (en) * | 2001-09-28 | 2012-11-13 | Mcneil-Ppc, Inc. | Film forming compositions containing sucralose |
| GB0129117D0 (en) * | 2001-12-05 | 2002-01-23 | Glaxo Group Ltd | Pharmaceutical composition |
| US20040052843A1 (en) * | 2001-12-24 | 2004-03-18 | Lerner E. Itzhak | Controlled release dosage forms |
| US20030228363A1 (en) * | 2002-06-07 | 2003-12-11 | Patel Mahendra R. | Stabilized pharmaceutical compositons containing benzimidazole compounds |
| WO2004009085A2 (en) * | 2002-07-19 | 2004-01-29 | Ranbaxy Laboratories Limited | Taste masked sumatriptan tablets and processes for their preparation |
| US7429619B2 (en) * | 2002-08-02 | 2008-09-30 | Mcneil Consumer Healthcare | Polyacrylic film forming compositions |
| US20040068000A1 (en) * | 2002-10-02 | 2004-04-08 | Mintong Guo | Compression coated tablets |
| ES2380827T3 (es) * | 2002-12-26 | 2012-05-18 | Pozen, Inc. | Formas de dosificación con múltiples capas que contienen naproxeno y triptanes |
| US20080213363A1 (en) * | 2003-01-23 | 2008-09-04 | Singh Nikhilesh N | Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa |
| WO2004076403A1 (en) * | 2003-02-24 | 2004-09-10 | Transform Pharmaceuticals, Inc. | Sumatriptan crystalline forms, pharmaceutical compositions and methods |
| AU2004247076A1 (en) * | 2003-06-06 | 2004-12-23 | Glaxo Group Limited | Composition comprising triptans and NSAIDs |
| US20070065463A1 (en) * | 2003-06-20 | 2007-03-22 | Ronald Aung-Din | Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions |
| GB2407498B (en) * | 2003-10-30 | 2008-06-11 | Cipla Ltd | Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient |
| GB0400452D0 (en) * | 2004-01-09 | 2004-02-11 | Norton Healthcare Ltd | A pharmaceutical composition |
| GB0403628D0 (en) * | 2004-02-18 | 2004-03-24 | Arrow Group Ltd | Compression-coated tablets and the manufacture thereof |
| ES2624585T3 (es) * | 2004-05-28 | 2017-07-17 | Imaginot Pty Ltd. | Sistema de suministro de compuesto terapéutico oral |
| US8216610B2 (en) * | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
| US20060002989A1 (en) * | 2004-06-10 | 2006-01-05 | Ahmed Salah U | Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same |
| MY147767A (en) | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
| BRPI0610864A2 (pt) | 2005-05-20 | 2010-08-03 | Janssen Pharmaceutica Nv | processo para preparação de derivados de sulfamida |
| CA2629904C (en) * | 2005-11-28 | 2018-07-10 | Imaginot Pty Ltd. | Oral therapeutic compound delivery system |
| WO2007070504A2 (en) * | 2005-12-13 | 2007-06-21 | Morton Grove Pharmaceuticals, Inc. | Stable and palatable oral liquid sumatriptan compositions |
| US8716231B2 (en) | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
| AR058389A1 (es) | 2005-12-19 | 2008-01-30 | Janssen Pharmaceutica Nv | Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad |
| US8497298B2 (en) | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
| US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
| US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
| RU2313340C1 (ru) * | 2006-02-20 | 2007-12-27 | Дмитрий Владимирович Зимин | Лекарственное средство, обладающее противомигренозным действием, и способ его изготовления |
| JP2009537635A (ja) | 2006-05-19 | 2009-10-29 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 癲癇の処置のための共同−療法 |
| JP2010522135A (ja) | 2006-10-09 | 2010-07-01 | チャールストン ラボラトリーズ，インコーポレイテッド | 医薬組成物 |
| BRPI0715579A2 (pt) | 2006-10-19 | 2015-05-26 | Auspex Pharmaceuticals Inc | "composto, composição farmacêutica e uso de um composto" |
| JP5714910B2 (ja) | 2008-01-09 | 2015-05-07 | チャールストン ラボラトリーズ，インコーポレイテッド | 薬学的組成物 |
| US20090252791A1 (en) * | 2008-04-02 | 2009-10-08 | Venkata Nookaraju Sreedharala | Pharmaceutical compositions comprising a triptan and a nonsteroidal anti-inflammatory drug |
| RU2424803C2 (ru) * | 2008-04-07 | 2011-07-27 | Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН (НИИ фармакологии имени В.В.Закусова РАМН) | Фармацевтическая композиция с противомигреневым действием (варианты) |
| CA2765866C (en) * | 2008-06-20 | 2016-06-21 | Alphapharm Pty Ltd | Single phase pharmaceutical composition of a 5-ht1 inhibitor and an nsaid |
| PE20110060A1 (es) | 2008-06-23 | 2011-01-31 | Janssen Pharmaceutica Nv | Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida |
| JP2011526889A (ja) * | 2008-06-30 | 2011-10-20 | アフギン ファーマ，エルエルシー | 局所局部的神経作用療法 |
| US8815939B2 (en) | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
| EP3311667A1 (de) | 2009-07-08 | 2018-04-25 | Charleston Laboratories, Inc. | Pharmazeutische zusammensetzungen |
| EP2480197B1 (de) | 2009-09-25 | 2015-11-11 | Dr. Reddy's Laboratories Ltd. | Formulierungen mit triptanverbindungen |
| US11337962B2 (en) | 2009-09-25 | 2022-05-24 | Upsher-Smith Laboratories, Llc | Formulations comprising triptan compounds |
| HK1244715A1 (zh) | 2015-03-02 | 2018-08-17 | 阿福金制药有限责任公司 | 用大麻素的局部区域神经影响性疗法 |
| US10383816B2 (en) | 2015-03-02 | 2019-08-20 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with cannabinoid combination products |
| JP2019507181A (ja) | 2016-03-04 | 2019-03-14 | チャールストン ラボラトリーズ，インコーポレイテッド | 医薬組成物 |
| US20180049994A1 (en) | 2016-08-16 | 2018-02-22 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with caryophyllene |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1170387B (it) * | 1982-06-07 | 1987-06-03 | Glaxo Group Ltd | Composti eterociclici, procedimento per prepararli e composizioni farmaceutiche che li contengono |
| GB8332437D0 (en) * | 1983-12-06 | 1984-01-11 | Glaxo Group Ltd | Chemical compounds |
| GB2162522B (en) * | 1984-08-01 | 1988-02-24 | Glaxo Group Ltd | An indole derivative |
| GB8419575D0 (en) * | 1984-08-01 | 1984-09-05 | Glaxo Group Ltd | Chemical compounds |
| GB8928208D0 (en) * | 1989-12-13 | 1990-02-14 | Glaxo Group Ltd | Medicaments |
| GB9104890D0 (en) * | 1991-03-08 | 1991-04-24 | Glaxo Group Ltd | Compositions |
-
1991
- 1991-03-08 GB GB919104890A patent/GB9104890D0/en active Pending
-
1992
- 1992-03-02 DE DE69225421T patent/DE69225421T2/de not_active Expired - Fee Related
- 1992-03-02 KR KR1019930702672A patent/KR100202042B1/ko not_active Expired - Fee Related
- 1992-03-02 CA CA002105180A patent/CA2105180C/en not_active Expired - Fee Related
- 1992-03-02 RU RU9393057724A patent/RU2098093C1/ru not_active IP Right Cessation
- 1992-03-02 GE GEAP19922601A patent/GEP20012549B/en unknown
- 1992-03-02 DK DK92103592T patent/DK0503440T3/da active
- 1992-03-02 CZ CS931849A patent/CZ282352B6/cs not_active IP Right Cessation
- 1992-03-02 EP EP92103592A patent/EP0503440B1/de not_active Expired - Lifetime
- 1992-03-02 US US08/381,422 patent/US5863559A/en not_active Expired - Fee Related
- 1992-03-02 WO PCT/EP1992/000460 patent/WO1992015295A1/en not_active Ceased
- 1992-03-02 AU AU13264/92A patent/AU663303B2/en not_active Ceased
- 1992-03-02 AT AT92103592T patent/ATE165973T1/de not_active IP Right Cessation
- 1992-03-02 JP JP4504967A patent/JP2986546B2/ja not_active Expired - Fee Related
- 1992-03-02 ES ES92103592T patent/ES2117015T3/es not_active Expired - Lifetime
- 1992-03-05 GB GB9204761A patent/GB2254784B/en not_active Expired - Fee Related
- 1992-03-06 ZA ZA921690A patent/ZA921690B/xx unknown
- 1992-03-06 CH CH727/92A patent/CH684242A5/fr not_active IP Right Cessation
- 1992-03-06 IL IL101162A patent/IL101162A/xx unknown
- 1992-03-06 MX MX9200992A patent/MX9200992A/es not_active IP Right Cessation
- 1992-03-06 BE BE9200230A patent/BE1005086A5/fr not_active IP Right Cessation
- 1992-03-06 IT ITRM920155A patent/IT1271495B/it active IP Right Grant
- 1992-03-06 NZ NZ241873A patent/NZ241873A/xx unknown
- 1992-03-06 FR FR9202709A patent/FR2673538B1/fr not_active Expired - Fee Related
- 1992-03-06 IE IE072692A patent/IE920726A1/en not_active IP Right Cessation
- 1992-03-06 NL NL9200423A patent/NL9200423A/nl active Search and Examination
-
1993
- 1993-08-19 OA OA60402A patent/OA09812A/en unknown
-
1994
- 1994-12-01 SG SG169294A patent/SG169294G/en unknown
-
1995
- 1995-02-09 HK HK19395A patent/HK19395A/xx not_active IP Right Cessation
-
1998
- 1998-02-20 CY CY201198A patent/CY2011A/en unknown
- 1998-07-24 US US09/121,530 patent/US6020001A/en not_active Expired - Fee Related
-
2000
- 2000-01-13 US US09/481,933 patent/US6368627B1/en not_active Expired - Fee Related
-
2002
- 2002-02-28 US US10/084,683 patent/US20020197318A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2098093C1 (ru) | Фармацевтическая композиция на основе суматриптана | |
| US6515010B1 (en) | Carvedilol methanesulfonate | |
| JP3636380B2 (ja) | 二重層オキカルバゼピン錠剤 | |
| JP2528130B2 (ja) | 経口投与形体の徐放性医薬組成物 | |
| TW550090B (en) | Stable oral pharmaceutical dosage forms for acid-unstable drug | |
| JP4159607B2 (ja) | 大量の薬物を含有する速崩壊性及び速溶解性組成物製造のための顆粒 | |
| JP3725542B2 (ja) | ピコサルフェート剤形 | |
| KR100421347B1 (ko) | 약학 혼합 제제 | |
| KR100202154B1 (ko) | 파라세타몰 및 돔페리돈을 함유한 필름 피복 정제 | |
| SK285152B6 (sk) | Enterický potiahnutý farmaceutický prostriedok a spôsob jeho prípravy | |
| EP1555022A1 (de) | Verbindung von acetaminophenol und tramadol mit verzögerter freisetzung | |
| JPH07223970A (ja) | 消化管内適所放出製剤 | |
| WO2006082523A2 (en) | Pharmaceutical sustained release composition of metformin | |
| CN104363896A (zh) | 恩替卡韦的药物组合物及制造方法 | |
| HU228040B1 (en) | Coated trimebutine maleate tablet | |
| JP2024009815A (ja) | アキシチニブを含有する医薬組成物 | |
| AU2006213439A1 (en) | Pharmaceutical composition of acid labile substances | |
| WO2005084648A1 (en) | Pharmaceutical compositions comprising candesartan cilexetil | |
| JP2002518330A (ja) | 処置方法 | |
| MXPA06010805A (es) | Formulacion de claritromicina de libracion prolongada. | |
| RU2464018C1 (ru) | Фармацевтическая композиция для лечения сердца пролонгированного действия | |
| JP2009525953A (ja) | ジバルプロ酸及びその誘導体の徐放性製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BA | A request for search or an international-type search has been filed | ||
| BB | A search report has been drawn up | ||
| BC | A request for examination has been filed | ||
| BN | A decision not to publish the application has become irrevocable |